Search

Your search keyword '"Daveluy, Amélie"' showing total 326 results
Start Over Author "Daveluy, Amélie"
326 results on '"Daveluy, Amélie"'

2. Augmentation des surdoses et décès en lien avec la consommation de méthadone durant la crise sanitaire liée au COVID-19 en 2020

Author

Frauger, Elisabeth, Fouilhé, Nathalie, Lacroix, Clémence, Daveluy, Amélie, Le Boisselier, Reynald, Bertin, Célian, Revol, Bruno, Carton, Louise, Chevalier, Cécile, Eiden, Céline, Gibaja, Valérie, Aquizerate, Aurélie, Chaouachi, Leila, Bouquet, Emilie, Roussin, Anne, Mallaret, Michel, and Micallef, Joëlle

Published
2024
Full Text
View/download PDF

3. Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study

Author

Aquizerate, Aurélie, Laforgue, Edouard-Jules, Istvan, Marion, Rousselet, Morgane, Gérardin, Marie, Jouanjus, Emilie, Libert, Frédéric, Caous, Anne-Sylvie, Djezzar, Samira, Boucher, Alexandra, Daveluy, Amélie, Eiden, Céline, Fauconneau, Bernard, Fournier-Choma, Christine, Gibaja, Valérie, Lacroix, Clémence, Lapeyre-Mestre, Maryse, Le Boisselier, Reynald, Revol, Bruno, Guerlais, Marylène, and Victorri-Vigneau, Caroline

Published
2023
Full Text
View/download PDF

8. Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network

Author

Gandolfo, Pauline, primary, Soeiro, Thomas, additional, Jouve, Élisabeth, additional, Revol, Bruno, additional, Daveluy, Amélie, additional, Bertin, Célian, additional, Eiden, Céline, additional, Gibaja, Valérie, additional, Chaouachi, Leila, additional, Pérault‐Pochat, Marie‐Christine, additional, Chevallier, Cécile, additional, Aquizérate, Aurélie, additional, Le Boisselier, Reynald, additional, Carton, Louise, additional, Lapeyre‐Mestre, Maryse, additional, Frauger, Élisabeth, additional, Lacroix, Clémence, additional, and Micallef, Joëlle, additional

Published
2024
Full Text
View/download PDF

13. Analgesic switching in chronic users of dextropropoxyphene in France.

Author

Daveluy, Amélie, Bryan, Michael Charles, Miremont‐Salamé, Ghada, Lassalle, Régis, Lacueille, Clémentine, Grelaud, Angela, Floccia, Marie, Haramburu, Françoise, Lapeyre‐Mestre, Maryse, Micallef, Joëlle, and Salvo, Francesco

Subjects
*OPIOID analgesics, *ANALGESICS, *DATABASES, *OPIOIDS, *DRUG utilization, *ACETAMINOPHEN, *CROSS-sectional method
Abstract

Background: The combination dextropropoxyphene/paracetamol (DXP/P) was the most prescribed opioid analgesic until its withdrawal in 2011. Objectives: This study investigated dispensations of analgesics in chronic users of DXP/P during the 18 months following its withdrawal. Methods: A cross‐sectional study repeated yearly was conducted by using the French reimbursement database from 2006 to 2015. Chronic DXP/P users were defined as patients who received at least 40 boxes of DXP/P in the year prior to withdrawal. Data on analgesic dispensing were analyzed at DXP/P withdrawal (T0) and then every 6 months for 18 months. Results: A total of 63 671 subjects had a DXP/P reimbursement in the year prior to its discontinuation, of whom 7.1% were identified as chronic users (mean age: 71.5 years, women: 68.7%). Among the patients taking DXP/P alone at T0 (74.6%), one fourth switched to a peripheral analgesic, one fourth to a combination of peripheral analgesic/opioid, one fourth to another opioid, and the others mainly discontinued their treatment (14.1%) or died. During the following 12 months, most of the subjects taking only peripheral analgesics continued this treatment, while half of the subjects with a combination of opioid/peripheral analgesic or taking only an analgesic remained on this type of treatment. Conclusion: Eighteen months after DXP/P withdrawal, more than 10% of patients stopped taking an analgesic. Vigilance is required regarding any change in analgesics by regularly reassessing patients' pain and, in the case of opioid treatments, by monitoring the risk of use disorders. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Addictovigilance contribution during COVID-19 epidemic and lockdown in France

Author

Bouquet, Emilie, Chaouachi, Leila, Chevallier, Cécile, Deheul, Sylvie, Eiden, Céline, Fouilhé, Nathalie, Fournier-Choma, Chistine, Frauger, Elisabeth, Guerlais, Marylène, Le Boisselier, Reynald, Miremont, Ghada, Roussin, Anne, Tournebize, Juliana, Lapeyre-Mestre, Maryse, Boucher, Alexandra, Daveluy, Amélie, Gibaja, Valérie, Jouanjus, Emilie, Mallaret, Michel, Peyrière, Helene, and Micallef, Joëlle

Published
2020
Full Text
View/download PDF

17. Nitrous oxide in France: Evolution of complications reported to the French monitoring system in the context of information from health authorities and regulatory measures

Author

Guerlais, Marylène, primary, Aquizerate, Aurélie, additional, Daveluy, Amélie, additional, Lionnet, Arthur, additional, Gerardin, Marie, additional, Duval, Mélanie, additional, Istvan, Marion, additional, Laforgue, Edouard-Jules, additional, and Victorri-Vigneau, Caroline, additional

Published
2023
Full Text
View/download PDF

21. Hexahydrocannabinol poisoning reported to French poison centres.

Author

Labadie, Magali, Nardon, Audrey, Castaing, Nadège, Bragança, Coralie, Daveluy, Amélie, Gaulier, Jean-Michel, El Balkhi, Souleiman, and Grenouillet, Marike

Abstract

Hexahydrocannabinol is a hexahydro derivative of cannabinol. Poisoning with hexahydrocannabinol was first observed in Europe in May 2022. This is a retrospective observational study of cases of self-reported hexahydrocannabinol exposure reported to French poison centres between 1 January 2022 and 31 May 2023. There were 37 cases, including 19 in May 2023. The median age of the patients was 36 (interquartile range 28–43) years, and most were men. Eight patients had a history of substance use disorder. The route of exposure was ingestion in 24, inhalation (smoking or vaping) in 10, inhalation and ingestion in two and sublingual in one. Clinical features were neurological (85 per cent), cardiovascular (61 per cent), gastrointestinal (33 per cent), psychiatric (27 per cent) and ocular (21 per cent). Fifty-nine per cent of the patients were hospitalized. In four patients, the Poisoning Severity Score was 0 (asymptomatic); in 15 patients, the Score was 1 (minor); in 16, the Score was 2 (moderate); and in two cases, the Score was 3 (severe). In 70 per cent of patients, the outcome was known, and all recovered. Testing of biological samples was only undertaken in six cases. Five patients had positive blood or urine tests for hexahydrocannabinol; in two patients, tetrahydrocannabinol and metabolites were also detected. In addition, there was an additional patient in whom Δ8- and Δ9-tetrahydrocannabinol was detected in the substances used. Clinical effects reported in this series included neuropsychiatric and somatic effects. Whilst these cases related to self-reported hexahydrocannabinol use, it is likely that tetrahydrocannabinol use also contributed to the effects in a substantial proportion of cases. This study has some limitations, such as the lack of available information due to the retrospective nature of the study. As a result, it probably overestimates the number of moderate and severe cases due to under-reporting of cases of little or no severity. Analysis of the patient's blood and urine was performed only in six patients, so we cannot be certain that the products consumed by the other patients were hexahydrocannabinol. The clinical effects attributed to hexahydrocannabinol were neurological, cardiovascular, gastrointestinal, psychiatric and ocular predominantly and were sometimes serious. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Dispositif pharmacoépidémiologique de surveillance des substances psychoactives : intérêts du programme national OPPIDUM du Réseau français d’addictovigilance

Author

Frauger, Elisabeth, Pochard, Liselotte, Boucherie, Quentin, Giocanti, Adeline, Chevallier, Cécile, Daveluy, Amélie, Gibaja, Valérie, Caous, Anne-Sylvie, Eiden, Céline, Authier, Nicolas, Le Boisselier, Reynald, Guerlais, Marylène, Jouanjus, Émilie, Lepelley, Marion, Pizzoglio, Véronique, Pain, Stéphanie, Richard, Nathalie, and Micallef, Joëlle

Published
2017
Full Text
View/download PDF

27. Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data

Author

Roussin, Anne, Soeiro, Thomas, Fouque, Charlotte, Jouanjus, Emilie, Frauger, Elisabeth, Fouilhé, Nathalie, Mallaret, Michel, Micallef, Joëlle, Lapeyre-Mestre, Maryse, Batisse, Anne, Chevallier, Cécile, Daveluy, Amélie, Deheul, Sylvie, Fournier-Choma, Christine, Guerlais, Marylène, Le Boisselier, Reynald, Pérault-Pochat, Marie‐christine, Roy, Sophie, Tournebize, Juliana, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Epidémiologie et analyses en santé publique : risques, maladies chroniques et handicaps (LEASP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Toulouse (UT), Institut de Neurosciences des Systèmes (INS), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital de la Timone [CHU - APHM] (TIMONE), Equipe EQUITY, Centre d'Epidémiologie et de Recherche en santé des POPulations (CERPOP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Service Pharmacologie Clinique [CHU Toulouse], Pôle Santé publique et médecine publique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Universitaire [Grenoble] (CHU), Addictovigilance Grenoble, Centre d'investigation clinique de Toulouse (CIC 1436), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Pôle Santé publique et médecine publique [CHU Toulouse], Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre antipoison et de toxicovigilance (Lyon) (CAPTV Lyon), Hospices Civils de Lyon (HCL), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Addictovigilance de Lille, Service de Pharmacologie Clinique [Nantes], Centre hospitalier universitaire de Nantes (CHU Nantes), Addictovigilance [Caen], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), and Agence Nationale de Securite du Medicament et des Produits de Sante, ANSM

Subjects
Adult, Analgesics, Opioid, Male, Pharmacology, Cross-Sectional Studies, Substance-Related Disorders, Humans, Pain, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Pharmacology (medical), France, Tramadol
Abstract

The aim of this paper is to assess recent developments in non-medical tramadol use, tramadol use disorder, illegal procurement and deaths.This study used repeated cross-sectional analysis of data collected nationwide from 2013 to 2018. Analysis was conducted through multisource monitoring of the French Addictovigilance Network of: (1) validated reports of high-risk tramadol use, (2) record systems collecting information from toxicology experts investigating analgesic-related deaths (DTA) and deaths related to substance abuse (DRAMES), and pharmacists for forged prescriptions (OSIAP), and (3) survey of drug users, with investigation of patterns of use while visiting addiction-specialised institutions (OPPIDUM).Despite a plateauing level of tramadol exposure in the French population, the proportion of tramadol reports increased 1.7-fold (187 cases in 2018, 3.2% (95% confidence interval [CI]: 2.74-3.63%), versus 1.9% (95% CI: 1.49-2.42% in 2013). Trends were similar in OSIAP: 11.9% of forged prescriptions in 2018 (95% CI: 10.56-13.45%); 1.7-fold increase; in OPPIDUM: 0.76% (95% CI: 0.55-1.02); 2.2-fold increase; and DRAMES: 3.2% of drug abuse-related deaths in 2018 (95% CI: 1.89-5.16) versus 1.7% in 2013 (95% CI: 0.65-3.84). Tramadol was the primary opioid in analgesic-related deaths in DTA (45% in 2018). Two profiles of high-risk tramadol users were identified: (1) patients treated for pain or with tramadol persistence when pain disappeared (mainly women; mean age 44 years), and (2) individuals with non-medical use for psychoactive effects (mainly men; mean age 36 years).The triangulation of the data obtained through addictovigilance monitoring evidenced a recent increase in high-risk tramadol use. These findings have a practical impact on the limitation of the maximal duration of tramadol prescriptions.

Published
2022

31. À propos de 12 cas d’intoxication au protoxyde d’azote diagnostiqués au CHU de Bordeaux en 2021 : nécessité du dosage de l’homocystéine totale plasmatique, biomarqueur de la carence cellulaire en vitamine B12

Author

Redonnet-Vernhet, Isabelle, primary, Duval, Fanny, additional, Carla, Louis, additional, Nadal, Louis, additional, Ouallet, Jean-Christophe, additional, Solé, Guilhem, additional, Mesli, Samir, additional, Guibet, Claire, additional, Daveluy, Amélie, additional, and Le-Masson, Gwendal, additional

Published
2022
Full Text
View/download PDF

32. Évaluation du mésusage de l’alprazolam : données du réseau français d’addictovigilance

Author

Diaz, Laurine, primary, Eiden, Céline, additional, Jouanjus, Emilie, additional, Frauger, Elisabeth, additional, Fouilhé, Nathalie, additional, Djezzar, Samira, additional, Gibaja, Valérie, additional, Boucher, Alexandra, additional, Leboisselier, Reynald, additional, Libert, Frédéric, additional, Caous, Anne-Sylvie, additional, Monzon, Emilie, additional, Guerlais, Marylène, additional, Daveluy, Amélie, additional, Fauconneau, Bernard, additional, and Peyrière, Hélène, additional

Published
2022
Full Text
View/download PDF

34. Complications liées à l’usage de substances psycho-actives chez les mineurs : cas rapportés au réseau français d’addictovigilance de 2016 à 2021

Author

Menil-Meresse, Césarine, primary, Chaouachi, Leila, additional, Daveluy, Amélie, additional, Fournier-Choma, Christine, additional, Fouilhé, Nathalie, additional, Deheul, Sylvie, additional, Chevalier, Cécile, additional, Lacroix, Clémence, additional, Tournebize, Juliana, additional, Aquizerate, Aurelie, additional, Pain, Stephanie, additional, Ponte, Camille, additional, Batisse, Anne, additional, and Peyriere, Hélène, additional

Published
2022
Full Text
View/download PDF

35. Diazépam : résultats de la première enquête d’addictovigilance (2011–2020)

Author

Daveluy, Amélie, primary, Fouilhé, Nathalie, additional, Peyrière, Hélène, additional, Gibaja, Valérie, additional, Libert, Frédéric, additional, Caous, Anne-Sylvie, additional, Fauconneau, Bernard, additional, Leboisselier, Reynald, additional, Chevallier, Cécile, additional, Monzon, Emilie, additional, Ponte, Camille, additional, Djezzar, Samira, additional, Guerlais, Marylène, additional, Frauger, Elisabeth, additional, and Miremont-Salamé, Ghada, additional

Published
2022
Full Text
View/download PDF

42. Décès après consommation de substances psychoactives entre 2018 à 2020 en Aquitaine et Départements et Régions d’Outre-Mer

Author

Laviec, Nina, primary, Perino, Justine, additional, Paillou, Virginie, additional, Titier, Karine, additional, Benali, Larbi, additional, Dumestre, Véronique, additional, Daulouède, Jean-Pierre, additional, Latour, Véronique, additional, Auriacombe, Marc, additional, Fouilhé, Nathalie, additional, Miremont-Salamé, Ghada, additional, and Daveluy, Amélie, additional

Published
2022
Full Text
View/download PDF

44. Et si la methcathinone n’était pas le problème ?

Author

Paradis, Camille, primary, Vaucel, Jules-Antoine, additional, Bragança, Coralie, additional, Carla, Louis, additional, Gardère, Odile, additional, Saint-Val, Thierry, additional, Labadie, Magali, additional, and Daveluy, Amélie, additional

Published
2022
Full Text
View/download PDF

47. Psychoactive substance use among students: A cross‐sectional analysis

Author

Perino, Justine, primary, Tournier, Marie, additional, Mathieu, Clément, additional, Letinier, Louis, additional, Peyré, Alexandre, additional, Perret, Garance, additional, Pereira, Edwige, additional, Fourrier‐Réglat, Annie, additional, Pollet, Clothilde, additional, Fatseas, Mélina, additional, Tzourio, Christophe, additional, and Daveluy, Amélie, additional

Published
2022
Full Text
View/download PDF

50. Warning on increased serious health complications related to non-medical use of nitrous oxide

Author

Micallef, Joelle, primary, Mallaret, Michel, additional, Lapeyre-Mestre, Maryse, additional, Daveluy, Amélie, additional, Victorri-Vigneau, Caroline, additional, Peyrière, Hélène, additional, Debruyne, Danièle, additional, Deheul, Sylvie, additional, Bordet, Régis, additional, Chevallier, Cécile, additional, Perault-Pochat, Marie-Christine, additional, Le Boisselier, Reynald, additional, Libert, Frédéric, additional, Chaouachi, Leila, additional, and Gillet, Pierre, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results